CXCR4 and neoplasm: Moreover, AMD3100 administration attenuated the proportions of CD206+ and CXCR4+CD206+ macrophages and GFP+ tumor cells in the HIF2A-overexpressing exosome-treated group (Figure 6D, E and F).